Zevra Therapeutics/$ZVRA
1D1W1MYTD1Y5YMAX
About Zevra Therapeutics
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
- Ticker
- $ZVRA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 61
- Headquarters
- Boston, United States
- Website
- www.zevra.com
ZVRA Metrics
BasicAdvanced
$687M
12.05
$0.96
0.92
-
Price and volume
Market cap
$687M
Beta
0.92
52-week high
$15.04
52-week low
$7.16
Average daily volume
1.4M
Financial strength
Current ratio
5.167
Quick ratio
5.018
Long term debt to equity
0.4
Total debt to equity
0.687
Interest coverage (TTM)
6.84%
Profitability
EBITDA (TTM)
40.553
Gross margin (TTM)
95.46%
Net profit margin (TTM)
42.82%
Operating margin (TTM)
28.71%
Effective tax rate (TTM)
15.91%
Revenue per employee (TTM)
$2,230,000
Management effectiveness
Return on assets (TTM)
8.74%
Return on equity (TTM)
34.80%
Valuation
Price to earnings (TTM)
12.049
Price to revenue (TTM)
4.888
Price to book
3.15
Price to tangible book (TTM)
3.26
Price to free cash flow (TTM)
20.386
Free cash flow yield (TTM)
4.91%
Free cash flow per share (TTM)
0.568
Growth
Revenue change (TTM)
119.40%
Earnings per share change (TTM)
-1,252.91%
3-year revenue growth (CAGR)
101.86%
3-year earnings per share growth (CAGR)
22.06%
10-year earnings per share growth (CAGR)
-33.68%
What the Analysts think about ZVRA
Analyst ratings (Buy, Hold, Sell) for Zevra Therapeutics stock.
ZVRA Financial Performance
Revenues and expenses
ZVRA Earnings Performance
Company profitability
ZVRA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.